…a high relapse rate and ongoing MRI activity appear to be indicators of an inadequate response to disease-modifying therapy, according to the 15-year follow-up results of the MS Collaborative Study Group pivotal trial of beta-interferon-1a (Avonex) (Bermel et al. AAN 2009; abstract P02.117). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

…REPORT FROM THE 2009 AAN ANNUAL MEETING – High-dose vitamin D3 supplementation appears to be well tolerated and significantly reduces T cell reactivity, according to the results of a prospective Canadian trial (Burton et al. AAN 2009; abstract P01.110). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

…REPORT FROM THE 2009 AAN ANNUAL MEETING – Two studies have investigated the potential benefits of rituximab, a monoclonal antibody that targets CD20 B cells, in primary- and secondary-progressive MS (PPMS, SPMS). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…